ES2061604T3 - Un metodo de preparacion de productos genicos foraneos. - Google Patents

Un metodo de preparacion de productos genicos foraneos.

Info

Publication number
ES2061604T3
ES2061604T3 ES88118584T ES88118584T ES2061604T3 ES 2061604 T3 ES2061604 T3 ES 2061604T3 ES 88118584 T ES88118584 T ES 88118584T ES 88118584 T ES88118584 T ES 88118584T ES 2061604 T3 ES2061604 T3 ES 2061604T3
Authority
ES
Spain
Prior art keywords
ltr
downstream
foreign gene
preparation
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88118584T
Other languages
English (en)
Inventor
Toshiya Takano
Minoru S H Ko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2061604T3 publication Critical patent/ES2061604T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/12011—Betaretrovirus, e.g. mouse mammary tumour virus
    • C12N2740/12041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/12043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

UN METODO DE PRODUCCION DE PRODUCTOS DE GASES EXTRAÑOS QUE COMPRENDE (1) LA TRANSFORMACION DE CELULAS ANIMALES O (A) USANDO DOS PLASMIDOS, ES DECIR UN PLASMIDO CONTENIENDO EL MMTV LTR Y UN GEN EXTRAÑO ENVOLVIENDO UNA SUBSTANCIA FISIOLOGICAMENTE ACTIVA INSERTADA EN EL CORRIENTE ABAJO DESDE EL LTR Y UN PLASMIDO CONTENIENDO EL LTR Y UN GEN PROTEINICO RECEPTOR GLUCOCORTICOIDE INSERTADO EN EL CORRIENTE ABAJO DEL EL LTR O (B) USANDO UN PLASMIDO COMPRENDIENDO EL LTR, UN GEN PROTEINICO RECEPTOR GLUCOCORTICOIDE SITUADO CORRIENTE ABAJO DESDE EL LTR, OTRO LTR Y UN GEN EXTRAÑO ENVOLVIENDO UNA SUBSTANCIA FISIOLOGICAMENTE ACTIVA SITUADA CORRIENTE ABAJO DONDE EL ULTIMO LTR, Y (2) EL CULTIVO DE CELULAS ANIMALES TRANSFORMADAS EN UN MEDIO CONTENIENDO GLUCOCORTICOIDES EN UNA CANTIDAD EFECTIVA PARA INDUCIR LA TRANSCRIPCION DEL MRNA.
ES88118584T 1987-11-09 1988-11-08 Un metodo de preparacion de productos genicos foraneos. Expired - Lifetime ES2061604T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28289387 1987-11-09

Publications (1)

Publication Number Publication Date
ES2061604T3 true ES2061604T3 (es) 1994-12-16

Family

ID=17658465

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88118584T Expired - Lifetime ES2061604T3 (es) 1987-11-09 1988-11-08 Un metodo de preparacion de productos genicos foraneos.

Country Status (6)

Country Link
US (2) US5646013A (es)
EP (1) EP0316717B1 (es)
AT (1) ATE101198T1 (es)
CA (1) CA1309044C (es)
DE (1) DE3887635T2 (es)
ES (1) ES2061604T3 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318500A4 (en) * 1986-08-01 1989-12-22 Genetics Inst INDUCIBLE HIGH MIRROR EXPRESSION FOR HETEROLOGICAL GENES.
CA2059317A1 (en) * 1991-01-15 1992-07-16 Yi Zeng Immuno-enzymatic test for detection of hiv-1 antibody
US5665873A (en) * 1995-02-09 1997-09-09 Dana Farber Cancer Institute Glucocorticoid response elements
FR2782732A1 (fr) * 1998-08-28 2000-03-03 Transgene Sa Systeme d'expression inductible
US6268178B1 (en) 1999-05-25 2001-07-31 Phage Biotechnology Corp. Phage-dependent super-production of biologically active protein and peptides
CA2524619A1 (en) * 2005-11-22 2007-05-22 Ottawa Health Research Institute Novel stem cells, nucleotide sequences and proteins therefrom

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH657141A5 (de) * 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
US4374927A (en) * 1981-02-24 1983-02-22 The Board Of Trustees Of The Leland Stanford Jr. University Extrachromosomal regulation of expression
EP0105141A3 (en) * 1982-09-09 1985-12-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant dna molecules, process for their production, their use for production of hepatitis b surface antigen (hbsag) and pharmaceutical compositions containing this hbsag
JPH0630590B2 (ja) * 1985-08-30 1994-04-27 株式会社ヤクルト本社 複合プラスミドベクタ−
EP0213628A3 (en) * 1985-09-03 1988-09-21 Yeda Research And Development Company, Ltd. Expression of superoxide dismutase in eukaryotic cells
EP0318500A4 (en) * 1986-08-01 1989-12-22 Genetics Inst INDUCIBLE HIGH MIRROR EXPRESSION FOR HETEROLOGICAL GENES.
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays

Also Published As

Publication number Publication date
DE3887635T2 (de) 1994-06-01
US5646013A (en) 1997-07-08
ATE101198T1 (de) 1994-02-15
EP0316717A1 (en) 1989-05-24
US5534419A (en) 1996-07-09
CA1309044C (en) 1992-10-20
DE3887635D1 (de) 1994-03-17
EP0316717B1 (en) 1994-02-02

Similar Documents

Publication Publication Date Title
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
ES2049070T3 (es) Preparacion de saborizantes.
WO1996027006A3 (en) Human vegf-specific antisense oligonucleotides
DE68922917D1 (de) KEX2-Endoprotease und Verfahren zu ihrer Herstellung.
ES2061604T3 (es) Un metodo de preparacion de productos genicos foraneos.
FR2563434B1 (fr) Vaccin contre la rage et procede pour sa preparation
DK404486D0 (da) Medikament-polymergrundmasse-praeparat og fremgangsmaade til dets fremstilling
WO1999047678A3 (en) Interferon alpha plasmids and delivery systems, and methods of making and using the same
NO971139D0 (no) Fremgangsmåte for fremstilling av rekombinante proteiner, plasmider og modifiserte celler
IT8919050A0 (it) Procedimento per la introduzione di dna esogeno nelle cellule somatiche e germinali di animali.
DE68927055D1 (de) 2',5'-oligoadenylat-derivate zur verwendung als heilmittel
PT80221B (en) Improved process for preparing benzamide derivatives useful as anticonvulsant agents
PT86771A (pt) Process for preparing 4-substituted benzamide derivatives with anticonvulsant activity
FR2600079B1 (fr) Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
ES498451A0 (es) Procedimiento para la preparacion de un polipeptido
MX9801550A (es) Uso de muteinas de citocinas de tipo silvestre como inmunogenos.
FR2565202B1 (fr) Dispositif de preparation de commandes de produits groupes sous forme d'ensembles, en particulier de cigarettes
DE3867647D1 (de) Einrichtung zur reizung der speichelabsonderung.
MA20381A1 (fr) Procede de preparation de gamma-interferon humain par la technologie des genes
MA21307A1 (fr) Plantes qui supportent la tension et methode pour leur preparations.
TW226409B (es)
SE8704497L (sv) Avstaembar bragglaser
Iordan et al. Effect of vitamin B sub (12) on DNA synthesis of Propionibacterium
IT8784934A0 (it) Procedimento per ottenere pietre artificiali da pavimenti e rivestimenti e pietre cosi'ottenute.
IT7924227A0 (it) Metodo per la terapia dell'artrite reumatoide e formulazioni farmaceutiche idonee allo scopo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 316717

Country of ref document: ES